Intensity Therapeutics Seeks Reverse Stock Split to Maintain Nasdaq Listing

TL;DR

**INTS is doing a reverse split to stay on Nasdaq, but don't expect a miracle — it's a band-aid, not a cure.**

AI Summary

Intensity Therapeutics, Inc. (INTS) is holding a Special Meeting on October 22, 2025, to seek stockholder approval for a reverse stock split of its common stock. The proposed reverse stock split ratio will be between one-for-five and one-for-thirty, with the exact ratio to be determined by the board of directors. This action is primarily aimed at meeting Nasdaq's listing requirements, specifically the minimum bid price rule. The board also seeks approval for an adjournment of the meeting, if necessary, to solicit additional proxies for the reverse stock split. As of the record date, August 29, 2025, there were 49,055,462 shares of common stock outstanding and entitled to vote. The board of directors unanimously recommends a 'FOR' vote on both the reverse stock split and the adjournment proposals.

Why It Matters

A reverse stock split for Intensity Therapeutics is a critical move to avoid delisting from Nasdaq, which could severely impact the stock's liquidity and investor confidence. For investors, this could be a double-edged sword: while it preserves exchange listing, it often signals underlying financial distress and doesn't guarantee a sustained price increase. Employees might see this as a necessary step to maintain company viability and access to capital markets. In the competitive biotech landscape, maintaining a public listing is crucial for attracting investment and talent, and a delisting could put INTS at a significant disadvantage against peers.

Risk Assessment

Risk Level: high — The primary risk is that the reverse stock split, while intended to meet Nasdaq's minimum bid price requirement, does not guarantee a sustained increase in stock price. Historically, reverse splits often lead to further price declines, and the company's need for such a measure suggests underlying operational or financial challenges. The board's discretion to set the ratio between one-for-five and one-for-thirty also introduces uncertainty for investors.

Analyst Insight

Investors should carefully evaluate Intensity Therapeutics' underlying business fundamentals and clinical pipeline, as a reverse stock split alone does not address operational issues. Consider the potential for further dilution or price erosion post-split and assess if the company has a clear path to profitability or significant clinical milestones before making any investment decisions.

Key Numbers

• 49,055,462 — Shares Outstanding (Number of common stock shares entitled to vote as of August 29, 2025 record date)
• 1:5 to 1:30 — Reverse Stock Split Ratio Range (Proposed range for the reverse stock split, exact ratio to be set by the board)
• October 22, 2025 — Special Meeting Date (Date stockholders will vote on the reverse stock split proposal)
• August 29, 2025 — Record Date (Date for determining stockholders eligible to vote at the Special Meeting)
• 16,351,821 — Quorum Requirement (Minimum number of shares needed to be present or represented for a valid meeting)

Key Players & Entities

• INTENSITY THERAPEUTICS, INC. (company) — Registrant seeking stockholder approval for reverse stock split
• Lewis H. Bender (person) — President, Chief Executive Officer and Chairman of Intensity Therapeutics, Inc.
• Joseph Talamo (person) — Contact person for Intensity Therapeutics, Inc. for proxy materials
• Nasdaq (regulator) — Stock exchange whose listing requirements the company aims to meet
• Securities and Exchange Commission (regulator) — Regulatory body for filing DEF 14A
• Continental Stock Transfer & Trust Company (company) — Transfer agent for Intensity Therapeutics, Inc.
• $49,055,462 (dollar_amount) — Number of shares of common stock outstanding and entitled to vote as of August 29, 2025
• $16,351,821 (dollar_amount) — Minimum number of shares required for a quorum (one-third of outstanding shares)

FAQ

Risk Factors

• Nasdaq Listing Requirements [high — regulatory]: The company is seeking approval for a reverse stock split to comply with Nasdaq's minimum bid price rule. Failure to maintain the minimum bid price could result in delisting from the Nasdaq Capital Market, which would significantly impact liquidity and investor confidence.

Industry Context

Intensity Therapeutics operates in the biotechnology sector, a highly competitive and capital-intensive industry. Companies in this space often face significant challenges in drug development, clinical trials, and regulatory approvals. Maintaining a listing on major exchanges like Nasdaq is crucial for access to capital and investor visibility, making compliance with listing rules a paramount concern.

Regulatory Implications

The primary regulatory concern for Intensity Therapeutics is compliance with Nasdaq's minimum bid price rule. Failure to meet this requirement could lead to delisting, severely impacting the company's ability to raise capital and its market valuation. The proposed reverse stock split is a direct measure to address this regulatory hurdle.

What Investors Should Do

1. Vote FOR the Amendment Proposal (Reverse Stock Split)
2. Vote FOR the Adjournment Proposal

Key Dates

• 2025-10-22: Special Meeting of Stockholders — Stockholders will vote on the proposed reverse stock split and adjournment proposals. The outcome is critical for the company's Nasdaq listing status.
• 2025-08-29: Record Date — Determined the stockholders eligible to vote at the Special Meeting. 49,055,462 shares of common stock were outstanding and entitled to vote.
• 2025-09-09: Mailing of Proxy Materials — Commencement of distribution of proxy statements and related materials to stockholders for the Special Meeting.

Glossary

Reverse Stock Split

A corporate action where a company reduces the number of its outstanding shares by consolidating them into fewer, proportionally more valuable shares. (The primary purpose of this meeting is to gain stockholder approval for a reverse stock split to meet Nasdaq's minimum bid price requirement.)

DEF 14A

A proxy statement filing required by the SEC for companies holding annual or special meetings of shareholders, containing detailed information about matters to be voted on. (This document provides the essential information for stockholders to understand and vote on the proposed reverse stock split and adjournment.)

Proxy

A document or instruction authorizing another person to act as one's agent or representative, typically in voting shares at a shareholder meeting. (The company is soliciting proxies to ensure sufficient votes for the reverse stock split proposal, and the adjournment proposal is to allow for further proxy solicitation if needed.)

Year-Over-Year Comparison

This filing is focused on a specific corporate action (reverse stock split) rather than a comprehensive review of financial performance compared to the previous year. Therefore, direct year-over-year comparisons of revenue, margins, or net income are not the primary focus of this DEF 14A. The key change highlighted is the proactive measure to address potential delisting from Nasdaq.

Key Financial Figures

• $1.00 — shares of our common stock of at least $1.00 per share (also referred to as the "min
• $0.10 — common stock has a closing bid price of $0.10 per share or less for ten consecutive t
• $1.00 b — mon stock will remain above the minimum $1.00 bid price required for any post-split Nas

Filing Documents

• intensity-20250904.htm (DEF 14A) — 175KB
• intensity-20250904_g1.jpg (GRAPHIC) — 42KB
• intensity-20250904_g2.jpg (GRAPHIC) — 440KB
• intensity-20250904_g3.jpg (GRAPHIC) — 176KB
• 0001567264-25-000090.txt ( ) — 1822KB
• intensity-20250904.xsd (EX-101.SCH) — 1KB
• intensity-20250904_htm.xml (XML) — 1KB

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 14 ADDITIONAL INFORMATION 16 APPENDIX A Appendix A-1 APPENDIX B Appendix B-1 i Intensity Therapeutics, Inc. 1 Enterprise Drive, Suite 430 Shelton, CT 06484 PROXY STATEMENT FOR THE SPECIAL MEETING OF STOCKHOLDERS TO BE HELD ON OCTOBER 22, 2025 This proxy statement (the "Proxy Statement") is furnished to stockholders of Intensity Therapeutics, Inc., a Delaware corporation (the "Company," "we," "us," or "our"), in connection with the solicitation of proxies by our board of directors for use at a special meeting of stockholders to be held on October 22, 2025, and at any adjournment or postponement thereof (our "Special Meeting"). Our Special Meeting will be held at 10:30a.m. Eastern time via a live audio webcast at www.virtualshareholdermeeting.com/INTS2025SM. On or about September 9, 2025, we will commence mailing of the proxy materials which are also available at www.proxyvote.com. The proxy materials are being sent to stockholders who owned our common stock at the close of business on August 29, 2025, the record date for the Special Meeting (the "Record Date"). This Proxy Statement contains important information for you to consider when deciding how to vote on the matters brought before the meeting. Please read it carefully. Why am I receiving these materials? We sent you this Proxy Statement because our board of directors is soliciting your proxy to vote at our Special Meeting. This Proxy Statement summarizes the information you need to vote at our Special Meeting. You do not need to attend our Special Meeting to vote your shares. What proposals will be voted on at the Special Meeting? Stockholders will vote on two proposals at the Special Meeting: 1. The approval of an amendment to our Amended and Restated Certificate of Incorporation, as amended (the "Amended and Restated Certificate of Incorporation"), to effect a reverse stock split of our common stock by a ratio of

View Full Filing

View this DEF 14A filing on SEC EDGAR